Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Biofrontera (BFRIW) over the last 4 years, with Q3 2025 value amounting to $225000.0.

  • Biofrontera's Gains from Sales and Divestitures rose 461599.25% to $225000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $225000.0, marking a year-over-year increase of 461599.25%. This contributed to the annual value of $4771.0 for FY2024, which is 4444.57% down from last year.
  • Biofrontera's Gains from Sales and Divestitures amounted to $225000.0 in Q3 2025, which was up 461599.25% from $4771.0 recorded in Q4 2024.
  • Biofrontera's Gains from Sales and Divestitures' 5-year high stood at $170.1 million during Q2 2022, with a 5-year trough of $4771.0 in Q2 2024.
  • Over the past 4 years, Biofrontera's median Gains from Sales and Divestitures value was $8588.0 (recorded in 2023), while the average stood at $18.9 million.
  • As far as peak fluctuations go, Biofrontera's Gains from Sales and Divestitures crashed by 9495.03% in 2023, and later soared by 461599.25% in 2025.
  • Biofrontera's Gains from Sales and Divestitures (Quarter) stood at $8504.0 in 2022, then grew by 0.99% to $8588.0 in 2023, then crashed by 44.45% to $4771.0 in 2024, then surged by 4615.99% to $225000.0 in 2025.
  • Its Gains from Sales and Divestitures was $225000.0 in Q3 2025, compared to $4771.0 in Q4 2024 and $4771.0 in Q3 2024.